High Quality White Crystal Powder Linagliptin Treat Type II Diabetes 668270 -12-0

China High Quality White Crystal Powder Linagliptin Treat Type II Diabetes 668270-12-0, Find details about China 668270-12-0, Linagliptin from High Quality White Crystal Powder Linagliptin Treat Type II Diabetes 668270-12-0

Basic Info.

Model NO.

668270-12-0

CAS

668270-12-0

Storage

Cool Dry Place

Einecs

922-028-0

C20h17brn6o2

Appearance

White Crystal Powder

Trademark

Biocar

Transport Package

Bag or Drum

Specification

1kg/Bag; 25kg/Drum

Origin

Wuhan China

HS Code

3002200000

Model NO.

668270-12-0

CAS

668270-12-0

Storage

Cool Dry Place

Einecs

922-028-0

C20h17brn6o2

Appearance

White Crystal Powder

Trademark

Biocar

Transport Package

Bag or Drum

Specification

1kg/Bag; 25kg/Drum

Origin

Wuhan China

HS Code

3002200000

Product Desciption

High Quality White Crystal Powder Linagliptin Treat Type II Diabetes 668270-12-0

Basic Information
Linagliptin, also known as BI-1356, is a DPP-4 inhibitor developed by Boehringer Ingelheim for treatment of type II diabetes.
Properties: White Powder
Density:   1.6±0.1 g/cm3
Boiling Point:   558.8±60.0ºC at 760 mmHg
Flash Point:   291.8±32.9ºC
High Quality White Crystal Powder Linagliptin Treat Type II Diabetes 668270-12-0

Application

Linagliptin is a kind of dipeptide peptidase 4 (DPP - 4) inhibitors used as dietary and exercise in type 2 diabetes in adult auxiliary treatment to improve blood sugar control.
Linagliptin is used with a proper diet and exercise program and possibly with othermedications to control high blood sugar. It is used by people with type 2 diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke.

Functions
1. Incretin (Incretin) has the role of intestinal promoting in sulin B cells to secrete in sulin, mainly including glucose-dependent in sulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). DDP-4 is a serine protease located on the cell surface, which is widely found in plasma and in vivo tissues (such as kidney, liver, small intestine villi, endothelial cells, etc.). Rilalitine is a selective DPP-4 inhibitor that inhibits the activity of the enzyme by reversibly binding to DPP-4, delays GLP-1 degradation, enhances GLP-1 activity, and stimulates glucose-dependent In sulin secretion, and reduce circulating levels of glucagon, thereby regulating blood glucose levels in patients with type 2 diabetes.

2. Compared with other DPP-4 inhibitors, the main advantages of liradetine is: with excellent renal safety, and can effectively reduce glycosylated hemoglobin. Lilardine mainly in the form of excretion of fecal excretion, the oral administration, the amount of renal excretion is only 5% of the dose, even if the intravenous administration, and only 30.8% of the excretion by the kidney, so the patient did not need treatment Regularly check the liver, kidney function and dose adjustment, all patients can be a unified fixed dose, easy to prescribe.

COA

items	Specifications	Results
Appearance	White or off-white crystalline powder	Conforms
HPLC	The retention time of the major peaking the chromatogram of the sample corresponds to that exhibited by the working standard	Conforms
Loss on drying	No more than 1.0%	0.40%
Residue on Ignition	No more than 0.1%	0.02%
Heavy Metals	No more than 20ppm	<10ppm
Related substances	Total impurities no more than 1.0%	0.50%
	Single impurity no more than 0.5%	Conforms
Residual solvents	Ethyl acetat No more than 0.1%	Conforms
	Ethanol No more than 0.1%	Conforms
Purity	No less than 99.0%	99.50%